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Abstract: Migraine is an important socioeconomic burden and is ranked the sixth cause of 
years of life lost because of disability in the general population and the third cause of years 
of life lost in people younger than 50 years. The cornerstone of pharmacological treatment is 
represented by the acute therapy. The serotonin (5-hydroxytryptamine [5-HT]) receptor subtype 
1
B
/1
D
 agonists, called triptans, are nowadays the first-line acute therapy for patients who experi-
ence moderate-to-severe migraine attacks. Unfortunately, a high percentage of patients are not 
satisfied with this acute treatment, either for lack of response or side effects. Moreover, their 
mechanism of action based on vasoconstriction makes them unsuitable for patients with previ-
ous cardio- and cerebrovascular diseases and for those with uncontrolled hypertension. Since 
the introduction of triptans, no other acute drug class has passed all developmental stages. The 
research for a new drug lacking vasoconstrictive effects led to the development of lasmiditan, a 
highly selective 5-HT1
F
 receptor agonist with minimized interactions with other 5-HT receptor 
subtypes. Lasmiditan is considered to be the first member of a new drug category, the neurally 
acting anti-migraine agent (NAAMA). Phase II and III trials had shown superiority compared 
to placebo and absence of typical triptan-associated adverse events (AEs). Most of the AEs 
were related to the central nervous system, depending on the high permeability through the 
blood–brain barrier and mild to moderate severity. The results of ongoing long-term Phase III 
trials will determine whether lasmiditan will become available in the market, and then active 
triptan comparator studies will assess patients’ preference. Future studies could then explore 
the safety during pregnancy and breastfeeding or the risk that overuse of lasmiditan leads to 
medication overuse headache.
Keywords: migraine, acute treatment, lasmiditan, 5-HT1
F
 agonists
Introduction
Migraine is a primary headache disorder characterized by moderate-to-severe headache 
attacks lasting 4–72 hours with unilateral location and pulsating quality, aggravated 
by movement or causing avoidance of routine physical activity and associated with 
nausea and/or vomiting, photophobia, and phonophobia.1 Migraine is an important 
socioeconomic burden and is ranked the sixth cause of years of life lost because of 
disability in the general population and the third cause of years of life lost in people 
younger than 50 years.2–5
Migraine is an episodic disorder, but its frequency during the lifetime can fluctu-
ate back and forth from a low to a high pattern. Each year, ~3% of patients with epi-
sodic migraine develop new-onset chronic migraine (CM), with headache occurring 
≥15 days/month (for >3 months with at least eight attacks having migraine features).1 
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When the frequency of the attacks is four or more per month, 
a preventative therapy with one or more of the following 
pharmacological classes is required: antihypertensive agents 
(e.g., β-blockers, calcium channel blockers, angiotensin-
converting enzyme [ACE] inhibitors, aldosterone receptor 
blockers), antiepileptic drugs (e.g., topiramate, divalproex 
sodium), and tricyclic antidepressants (e.g., amitriptyline, 
nortriptyline).6 Botox® (onabotulinumtoxinA) is indicated 
for the prevention of CM.
The cornerstone of pharmacological treatment is repre-
sented by the acute therapy, aimed to abort attacks and lead 
to a prompt relief from pain. Migraine acute therapy is based 
on nonspecific (analgesics and nonsteroidal anti-inflammatory 
drugs [NSAIDs]) or specific (triptans and ergot derivatives) 
drugs. The choice may be based on a stratified care approach 
(i.e., depending on migraine severity and other clinical factors) 
or on the step care management (i.e., if the response to anal-
gesics is not sufficient, patients might receive specific drugs).7
Current acute treatments
Triptans (5-HT1B/1D receptor agonists)
The serotonin (5-hydroxytryptamine [5-HT]) receptor sub-
type 1B/1D agonists (triptans) are nowadays the first-line 
acute therapy for patients who experience moderate-to-
severe migraine attacks. Since the introduction of Sumavel 
DosePro® (sumatriptan) in 1991, other triptan compounds 
with improved pharmacokinetic properties, efficacy, and 
safety were developed. They are more lipophilic than sumat-
riptan and consequently more capable to penetrate the blood–
brain barrier (BBB), thereby reaching their site of action more 
readily. Currently, seven triptans are available; in order of 
release, they are as follows: sumatriptan, zolmitriptan, riza-
triptan, naratriptan, eletriptan, almotriptan, and frovatriptan.
All triptans are superior to placebo and can be consid-
ered as effective and safe drugs for the vast majority of 
migraine patients.8 Despite a similar molecular structure, 
each triptan has its own pharmacokinetic and pharmaco-
dynamic profile. Some of them have characteristics similar 
to  sumatriptan,  displaying a rapid dose-dependent efficacy 
with a higher risk of adverse effects (AEs), while others 
have a slower relieving effect on migraine symptoms but a 
more prolonged duration of action and less recurrence of 
migraine attacks.
Safety and contraindications
Triptans bind mostly to 5-HT1
B
 and 5-HT1
D
 receptors 
within cerebral blood vessels (endothelium), leading to a 
rather selective vasoconstriction and inhibiting the release 
of neurogenic inflammatory mediators such as calcitonin 
gene-related peptide (CGRP).9
The 5-HT1
B
/1
D
 receptors are also present on coronary and 
limb arteries.10,11 Accordingly, triptan administration causes a 
reduction in coronary artery diameter and a brief constriction 
of limb arteries.11,12 Although these minor constrictions are 
unlikely to cause symptoms and the risk for cardiovascular 
events is very low in normal patients, triptans may possibly 
cause ischemia in those with coronary disease.10 Rare cases 
of stroke, myocardial infarction, and arrhythmia have been 
reported in temporal relation to use of triptans.13–15 For this 
reason, patients with myocardial infarction, coronary artery 
disease, stroke, uncontrolled hypertension, and vasculitis 
cannot use triptans. In addition, for patients with hemiplegic 
migraine or with prolonged migraine aura, as well as for 
pregnant women, triptans are not entirely recommended.16,17
Although they are safe drugs, class-related side effects 
(e.g., chest tightness and throat discomfort, muscle pain, and 
paresthesia) are reported by up to 24% of patients using oral 
triptans and by 40% of patients using subcutaneous formula-
tion.16 For instance, injectable formulation may be slightly 
uncomfortable at the site of injection and can potentiate the 
events known as triptan sensation.18
Migraineurs with four or more attacks per months need a 
preventative treatment. The frequent presence of comorbidi-
ties should drive the choice of a preventive drug, in order 
to reduce the medication intake and increase the efficacy 
for both the disorders.19 Consequently, choosing the safest 
acute therapy during migraine prophylactic treatment needs 
pharmacokinetic and pharmacodynamic considerations.20 
For example, triptans are contraindicated in patients with 
comorbid depression taking serotonin reuptake inhibitors 
due to the theoretical possibility of serotonergic syndrome.21
Limitations
An Australian pharmacoepidemiological study showed that 
total triptan use has increased at an average annual rate of 
112% over the 18-year period.22 Besides, only a minority of 
migraine patients use the specific antimigraine drug triptans 
(10% in Denmark, 17% in Italy, and 35% in France).23–25 The 
most probable reason is the relatively low efficacy. Over 35% 
of participants in randomized clinical trials (RCTs) do not 
benefit from administration of triptans, while others complain 
about their lack of consistency over time.8 Likewise, pain 
freedom rate at 2 hours after administration of triptans ranges 
from 12% (frovatriptan 2.5 mg) to 40% (rizatriptan 10 mg).26
More indeed, the American Migraine Prevalence and Pre-
vention Study found that 40% of episodic migraine patients 
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have unmet treatment needs, with dissatisfaction with current 
migraine medication (15%) and headache-related disability 
(19%) as the most frequent complaints.27 Therefore, over 
the past 5 years, most clinical studies investigated how to 
improve triptan therapy, increasing efficacy and decreasing 
adverse reactions. The two principal lines of research were 
the combination therapy and novel triptan administration 
routes and devices.28
Combination therapy
Most of the clinical trials studied combinations of triptans 
with NSAIDs, particularly combinations of sumatriptan 
and Trixemet® (naproxen). Recent systematic reviews have 
shown that sumatriptan–naproxen is more effective than 
placebo and sumatriptan or naproxen alone regarding pain 
free and pain relief.7,29–32 Compared to their usual migraine 
therapy, patients found the combination of sumatriptan–
naproxen to be superior in decreasing headache severity, 
lessening associated symptoms, and providing long-lasting 
relief with a high rate of complete relief with a single dose 
(60.04% of attacks resolved at 2 hours post treatment).33 
The use of sumatriptan–naproxen is associated with rapid 
and consistent restoration of patients’ functioning, faster 
recovery time in some measures of cognitive efficiency, 
and consistent reduction in productivity loss compared to 
placebo.34,35 In general, combination therapy has higher 
satisfaction ratings.33–35
The combination of another triptan, frovatriptan 2.5 mg, 
with two doses of a different NSAID, dexketoprofen 25 and 
37.5 mg, has been tested for the therapy of acute migraine.36 
Compared to frovatriptan alone, the group treated with the 
combination therapy had a significantly higher pain-free rate 
at 2 and 4 hours and sustained pain-free rate at 24 hours, with 
no statistically significant difference between participants 
treated with the dexketoprofen 25 or 37.5 mg combina-
tion.36 Sustained pain-free rate at 48 hours and recurrence of 
migraine were similar between the three groups, meaning a 
lack of improvement with the combination therapy.
Recently, a multicenter, randomized, double-blind trial 
evaluated the efficacy and safety of the combination of 
sumatriptan 50 mg plus an antiemetic agent promethazine 
25 mg.37 Significantly more patients receiving the combina-
tion therapy experienced 2- and 4-hour pain-free response and 
headache improvement response compared to those treated 
with sumatriptan alone. In addition, the incidence of headache 
recurrence within 2–48 hours after treatment was lowest in 
the sumatriptan–promethazine group. However, significant 
drug-related AEs were more frequent with combination 
therapy than with sumatriptan alone (somnolence in 32.2% 
and 7% patients and extrapyramidal symptoms in 4.3% and 
0% patients, respectively), while nausea was more frequent 
with triptan therapy alone (1% and 8% patients, respectively).
New formulations and device
Triptans are generally effective for migraine treatment but 
share one problem common to all oral drugs, the delayed 
absorption of the drug depending on the gastric stasis that 
occurs during the migraine attacks.38,39 This issue has led to 
the development of new administration routes and devices. 
Two Cochrane database systematic reviews have focused on 
intranasal and suppository sumatriptan.40,41 Both the formu-
lations have been effective in treating the attack, alleviating 
migraine-associated symptoms, and restoring functional 
disability.
A randomized, active-comparator, double-dummy, cross-
over, multi-attack study (COMPASS study) compared the 
efficacy and tolerability of AVP-825, a bidirectional breath-
powered intranasal delivery system containing low-dose 
(22 mg) sumatriptan powder vs. oral sumatriptan 100 mg.42 
Rates of pain relief and pain freedom at 2 hours and sustained 
pain freedom from 2 to 48 hours were similar, but at earlier 
time point, measured between 15 and 90 minutes, AVP-825 
was superior. Nasal discomfort and abnormal taste were 
more common with AVP-825, while atypical sensation rates 
were significantly lower than with conventional sumatriptan 
100 mg. A post hoc analysis found that AVP-825, compared 
to oral sumatriptan, led to a more rapid early reduction in 
overall nausea rate during the first hour, a reduced odds of 
nausea from 30 minutes to 2 hours following treatment, and 
a reduced risk of treatment-emergent nausea.43
Until recently, the subcutaneous administration route was 
dependent upon a needle-based mechanism. A needle-free 
subcutaneous sumatriptan is a nitrogen pressure subcutane-
ous delivery system approved for the acute treatment of 
migraine and cluster headache in the US and some European 
countries.44 A single dose of needle-free subcutaneous sumat-
riptan 6 mg demonstrated bioequivalence to a single dose 
of traditional, needle-based subcutaneous sumatriptan 6 mg 
when delivered into the abdomen or the thigh, but not into 
the arm, conferring relief as early as 10 minutes after dosing, 
whereas oral, rectal, and intranasal routes of administration 
do so in ~1 hour.18,45
In an open-label, multicenter study, sumatriptan was self-
administered by patients currently treated with triptans and 
less than very satisfied with their acute migraine therapy.46 
The efficacy results were consistent with those previously 
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observed with needle-based sumatriptan, but participants 
experienced a statistically significant and clinically relevant 
increase in satisfaction with therapy and enhanced confidence 
in treatment after use.
An alternative to current formulations is transdermal 
drug delivery, particularly iontophoresis. NP101® or Zecuity 
(formerly known as the Zelrix Migraine Patch) is a trans-
dermal sumatriptan iontophoretic patch designed to release 
6.5 mg of sumatriptan (comparable to subcutaneous 6 mg) 
over 4 hours by using low-level electrical energy to transport 
sumatriptan across the skin. In double-blind, randomized, 
placebo-controlled trials, transdermal sumatriptan was supe-
rior to placebo but had a generally low clinical efficacy (18% 
pain free rate at 2 hours) compared with conventional oral 
sumatriptan 50–100 mg.47,48 The patch is currently removed 
from the US market after postmarketing reports of application 
site reactions described as burns and scars.
CGRP targeting drugs
So far, no more recent acute antimigraine treatments have 
succeeded in passing all developmental stages. Small- 
molecule CGRP receptor antagonists, the so-called gepants, 
have been studied since the early 2000s and were promis-
ing attack therapies until few years ago. Despite positive 
Phase II and III trials demonstrating safety and efficacy, 
their development was terminated. Intravenous olcegepant 
(BIBN4096BS) was terminated because of difficulty devel-
oping an oral formulation, oral telcagepant (MK-0974) and 
MK-3207 were terminated for transaminase elevation, and 
BMS-927711, which did not show evidence of hepatotoxicity, 
was discontinued in 2012 for unknown reasons.49
The development of small-molecule CGRP receptor 
antagonists that seemed abandoned has resumed in 2015 
when Allergan purchased the rights of ubrogepant (MK-
1602) from Merck. In a completed Phase IIb dose-finding 
study, ubrogepant doses of 25, 50, and 100 mg were superior 
to placebo for the 2-hour pain freedom end point, showing 
a dose-dependent response.50 Triptan-associated AEs were 
not observed, and only nausea and dizziness were more 
common in the ubrogepant group than in the placebo group. 
Although there was no signal of transaminase elevation, 
subjects only received a single dose. A second Phase IIb 
pharmacokinetic study was recently completed, but results 
have not yet been published. There are two ongoing Phase 
III RCTs (NCT02867709 and NCT02867709) expected to 
be completed in March 2018. In both studies, subjects were 
randomized to treat a single migraine attack either with pla-
cebo or with one of two doses of ubrogepant (25 or 50 mg in 
the first study and 50 or 100 mg in the other study).
Lasmiditan overview
Chemistry
The first 5-HT1
F
 receptor agonist to be tested was LY334370.51 
This compound, while preserving the typical triptan indole 
core, showed a high selectivity for 5-HT1
F
 (100-fold selectiv-
ity for 5-HT1
B
 and 5-HT1
D
 receptors) and also for 5-HT1
A
 
receptors.52 Even so, its development was discontinued 
because of long-term safety concerns in animals.53 There-
fore, a new selective 5-HT1
F
 receptor agonist was developed 
changing the chemical structure of LY334370 by replacing the 
indole moiety with a pyridinoyl–piperidine scaffold. Lasmidi-
tan, formerly known as COL-144 and LY573144, is a novel 
5-HT receptor agonist with high affinity and selectivity for 
the 5-HT1
F
 receptor. Its chemical structure is more different 
from triptans than its predecessor LY334370 and accounts 
for its inclusion in a new drug class called ditans (Figure 1).54
Pharmacodynamics
LY334370 showed relative selectivity for 5-HT1
F
 receptor 
(100-fold selectivity for 5-HT1
F
 receptors than for 5-HT1
B
 and 
5-HT1
D
 receptors) and a substantial affinity for the 5-HT1
A
 
receptor.52 However, a concern rose about the possibility that 
plasma levels in the therapeutic range might be high enough to 
activate vascular 5-HT1
B
 receptors. Lasmiditan met the goal of 
developing a highly selective agonist for the 5-HT1
F
 receptor, 
structurally different from the triptans, with a greater 5-HT1
F
 
receptor selectivity than LY334370 and with minimized inter-
actions with 5-HT1
A
, 5-HT1
B
, and 5-HT1
D
 receptors to avoid 
potential concerns arising for its predecessor. In vitro binding 
studies showed a 450-fold higher selectivity and higher affinity 
for 5-HT1
F
 receptors than for 5-HT1
A
, 5-HT1
B
, and 5-HT1
D
 
receptors, and a low cross-reactivity with other members of 
the 5-HT1 receptor family, even if all of them are structurally 
homologous.55 Moreover, lasmiditan showed no significant 
affinity across a panel of receptors that are known to regulate 
vascular tone, the monoaminergic subtypes.55
In addition to targeting peripheral 5-HT1
F
 receptors, las-
miditan, being a high lipophilic substance, is able to penetrate 
the BBB and may act on centrally located receptors.55 This 
hypothesis is supported by the results of two animal models 
of migraine involving electrical stimulation of the trigeminal 
ganglion that are considered predictive for drug efficacy in acute 
migraine treatment. Oral administration of lasmiditan at a dose 
≥3 mg/kg blocked neurogenic inflammation through inhibition 
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of dural plasma protein extravasation and reduced expression of 
a proto-oncogene (c-Fos) in the trigeminal nucleus caudalis.55
The selective functional activity of lasmiditan was dem-
onstrated in vitro in cells expressing the human isoforms 
of the subtypes of the 5-HT1 receptors using a standard 
radioligand-binding assay ([35 S]-GTP γ S). While triptans 
had high potency and efficacy at human 5-HT1
B
 and 5-HT1
D
 
receptors, lasmiditan showed low potency at the vasocon-
strictor 5-HT1
B
 receptors.55 Moreover, lasmiditan (in doses 
up to 100 μM) did not cause vessel contraction in the rabbit 
saphenous vein, which is a surrogate model that predicts 
vasoconstriction in human coronary arteries.55 In contrast, 
sumatriptan led to a 50% vasoconstriction.
Because of the high selectivity for the 5-HT1
F
 receptors 
and the absence of vasoconstrictive effects, 5-HT1
F
 receptor 
agonists are considered a new drug category, the neurally act-
ing anti-migraine agent (NAAMA), acting through a unique 
and promising new antimigraine mechanism.54
Pharmacokinetics and metabolism
Lasmiditan has a mean oral bioavailability reported to 
be ~40%, and the maximum serum concentration of 
lasmiditan is reached between 1.5 and 2.5 hours (T
max
) 
after oral administration of 50–400 mg.56 There are no 
available data about the possible influence of gender and 
age on these parameters. A recent randomized, open-label 
study evaluated the relative bioavailability of lasmiditan 
(Table 1).57 The maximum serum concentration (C
max
), 
T
max
, and the area under the curve (AUC) of lasmiditan 
200 mg under fasted and fed conditions were evaluated in 
30 healthy subjects. C
max
 was, respectively, 322.8±122.0 
and 394.7±167.8 ng/mL (mean±SD); T
max
 was, respec-
tively, 1.5±1.0 and 2.5±1.0 hours (mean±SD); and AUC
0–t
 
was, respectively, 1892±746.0 and 2244±926.2 ng×h/mL 
(mean±SD). There are no data about lasmiditan half-life 
(t
1/2
) and metabolism; therefore, the existence of active and/
or inactive metabolites is unknown.
Figure 1 Comparison of chemical structure of sumatriptan and lasmiditan: 2D structure (A and C) and 3D conformer (B and D).
Sumatriptan
Lasmiditan
1-[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
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N
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O
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Phase I clinical trials
Five Phase I studies have been conducted for lasmiditan (four 
for the oral formulation and one for the intravenous formula-
tion).58 Peer-reviewed publications for the Phase I trials do not 
exist. In each of these studies, 40–55 healthy subjects were 
evaluated to test the safety, tolerability, pharmacodynamics, 
and pharmacokinetics of lasmiditan.
The first Phase I trial was performed in 2003 to evalu-
ate safety, tolerability, and pharmacokinetics of intravenous 
administration of lasmiditan (no published data available). In 
2008, two Phase I trials (COL MIG-102 and COL MIG-103) 
tested different oral formulations (oral solution, oral tablet, 
and sublingual) to evaluate their safety, tolerability, bioavail-
ability, and other pharmacokinetic parameters. Oral formu-
lations demonstrated to reach plasma levels associated with 
efficacy of the intravenous formulation without severe AEs.59 
The oral formulation dose at least effective as sumatriptan 
in acute migraine treatment was calculated to be ≥170 mg.60
In 2011, the Phase I study COL MIG-105 evaluated the car-
diac safety of lasmiditan. This randomized, double-blind study 
compared the effects on cardiac depolarization and repolarization 
duration and other cardiac safety parameters of oral lasmiditan 
(100 and 400 mg) with those of the antibiotic moxifloxacin 
(400 mg) and placebo. Lasmiditan at both doses did not cause QT 
prolongation compared to moxifloxacin that led to QT prolonga-
tion as seen in other published studies.61 Moreover, no arrhythmia 
or any proarrhythmic effects were reported with lasmiditan.
The last Phase I study investigated the effects of the fed 
and fasted states on pharmacokinetic parameters (C
max
, T
max
, 
AUC) and AEs.57 The fed condition was associated with an 
increase in C
max
, T
max
, and AUC and a lower rate of mild AEs.
Several Phase I clinical trials are currently undergoing, 
while others have been recently completed, but the results 
are not yet available (Table 2).
Phase II clinical trials
Two Phase II trials were conducted in 2007 and 2009 for 
the intravenous formulation and the oral formulation, 
respectively.56,62
The first study was a proof-of-concept and dose-finding, 
multicenter, randomized, double-blind, placebo-controlled 
trial that enrolled 130 migraine patients with a migraine 
history of ≥1 year and not taking prophylactic medication.62 
The adaptive treatment design of the study allowed the up- or 
down-titration of the study drug (either lasmiditan i.v. in doses 
of 2.5–45 mg or placebo) according to efficacy and AEs. The 
primary efficacy measure was headache response (improve-
ment from moderate or severe headache to mild or no head-
ache) at 2 hours. Better response was observed in the groups 
receiving lasmiditan compared to placebo (54.2%–75% vs. 
45.2%) with a significant dose–response relationship with 
increasing doses of lasmiditan and with doses of ≥20 mg 
being more effective. For lasmiditan 20 mg, the headache 
response was 64% with a therapeutic gain (percentage differ-
ence between active drug and placebo) of 19%. Accordingly, 
the use of rescue medication decreased while patients’ global 
impression improved significantly with the increasing dose. 
The onset of pain relief occurred in 20–40 minutes.
The second Phase II study was a dose-ranging, multi-
center, randomized, double-blind, placebo-controlled trial 
that enrolled 534 migraine patients with a migraine history 
of ≥1 year and not taking prophylactic medication.56 Patients 
were randomized to treat one migraine attack with a rapid 
disintegration tablet of lasmiditan (in doses of 50, 100, 200, 
and 400 mg) or placebo in a 1:1:1:1:1 ratio. Every lasmidi-
tan dose was superior to placebo for the primary efficacy 
measure (headache response at 2 hours) with a significant 
linear dose–response association. After 1 hour, all the doses, 
except the 50 mg dose, were superior to placebo, and the 
400 mg dose significantly reduced headache severity start-
ing as early as 30 minutes, and after 90 minutes, all groups 
reached statistical significance vs. placebo. The therapeutic 
gains for headache responses at 2 hours were 18%, 38%, 
29%, and 39% for 50, 100, 200, and 400 mg of lasmiditan, 
respectively, compared to placebo. The therapeutic gain of 
lasmiditan 400 mg (39%) was higher than that of the intra-
venous 20 mg, probably because of the dose difference (oral 
400 mg corresponds to i.v. dose of ~160 mg).26 The headache 
Table 1 Summary of pharmacokinetic characteristics of serotonin receptor agonists
Compound Dosing (mg) T1/2 (hours) Bioavailability (%) Tmax (hours) Cmax (ng/mL) AUC (0, ∞) (ng/mL¥h)
Sumatriptan Oral 50 2 14 2.5 27–30 118
Oral 100 2 24 2.5 54 158
NS 20 1.2–3 17 1 13 48
Lasmiditan Oral 200 – – 1.5±1.0a 322.8±122.0a 1892±746.0a
2.5±1.0b 394.7±167.8b 2244±926.2b
Notes: T1/2, elimination half-life; Tmax, time to maximum concentration; Cmax, maximum observed concentration. 
aFasted condition. bFed condition. Data from Lionetto et al18 
and Food-Effect Study in Healthy Subjects.57
Abbreviations: AUC, area under the curve; NS, nasal spray.
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Table 2 Summary of completed and ongoing Phase I clinical trials on lasmiditan
ID number Study name Primary outcome measures Completion date
NCT03247790 An open-label, two-period study to evaluate the 
pharmacokinetics of lasmiditan in migraineurs 
during acute migraine attacks and during inter-ictal 
periods
Cmax of lasmiditan in each period
AUC (0–∞) of lasmiditan in each period
March 2018
NCT03270644 Effect of lasmiditan on the heart rate and blood 
pressure in healthy subjects receiving oral doses of 
propranolol
Change in mean hourly heart rate as determined 
by Holter ambulatory monitoring
November 2017
NCT03182920 Effect of age on the pharmacokinetics, safety, and 
tolerability of lasmiditan in healthy subjects
Cmax of major lasmiditan metabolites in each 
period
AUC (0–∞) of major lasmiditan metabolites in 
each period
August 2017
NCT03040362 A Phase I study to investigate the absorption, 
metabolism, and excretion of [14C]-lasmiditan 
following single oral dose administration in healthy 
male and female subjects
Cmax based on plasma concentrations of lasmiditan
Tmax based on plasma concentrations of lasmiditan
AUC from hour 0 to the last measurable 
concentration based on plasma concentrations of 
lasmiditan
AUC (0–∞) of total radioactivity in blood/AUC 
(0–∞) of total radioactivity in plasma
AUC (0–∞) of lasmiditan in plasma/AUC (0–∞) of 
total radioactivity in plasma
May 2017
NCT03009162 A Phase I, multicenter, open-label, parallel-group 
adaptive pharmacokinetic single dose study of oral 
lasmiditan in subjects with normal and impaired 
renal function
Cmax based on plasma concentrations of lasmiditan
Tmax based on plasma concentrations of lasmiditan
AUC (0–∞)
Amount excreted in urine
Fraction of dose excreted in urine
Renal clearance
June 2017
NCT03308669 Safety, tolerability, and pharmacokinetics of 
lasmiditan when coadministered with topiramate in 
healthy subjects
Number of participants with one or more SAEs 
considered by the investigator to be related to 
study drug administration
December 2017
NCT03310411 A randomized, double-blind, four-period, crossover 
study to evaluate the cardiovascular effect of single 
oral doses of lasmiditan when coadministered with 
single oral doses of sumatriptan in healthy subjects
SBP per 24-hour ABPM December 2017
NCT03286218 A randomized, subject- and investigator-blind, 
placebo- and active-controlled study to assess the 
abuse potential of lasmiditan
Change from baseline in Emax of bipolar drug liking 
VAS scores
November 2017
NCT03252015 Multiple-ascending dose, safety, tolerability, 
pharmacokinetic, and drug–drug interaction study 
of lasmiditan
Number of participants with one or more SAEs 
considered by the investigator to be related to 
study drug administration
January 2018
NCT03076970 A randomized, double-blind, three period, cross-
over study to evaluate the effect of single oral 
doses of lasmiditan when coadministered with 
single oral doses of sumatriptan (Imitrex) in healthy 
male and female subjects
Change from pre dose to 24 hours in vital signs
Change from pre dose to 24 hours in ECGs
AEs
April 2017
NCT03040479 A Phase I, multicenter, open-label, parallel-
group, pharmacokinetic single dose study of oral 
lasmiditan in subjects with normal and impaired 
hepatic function
Cmax based on plasma concentrations of lasmiditan
Tmax based on plasma concentrations of lasmiditan
AUC (0–∞)
Apparent elimination rate constant
Terminal elimination half-life
July 2017
NCT03012334 A Phase I, randomized, double-blind, placebo-
controlled, five-period, cross-over study assessing 
the effects of lasmiditan on simulated driving 
performance in normal healthy volunteers
Simulated driving performance in healthy subjects 
as measured by SDLP using the CRCDS-MiniSim
June 2017
Notes: Cmax, maximum observed concentration; AUC (0–∞), area under the concentration vs. time curve from zero to infinity; Tmax, time to maximum concentration; Emax, 
maximal effect score. Data from clinicaltrials.gov.
Abbreviations: SAE, serious adverse event; SBP, systolic blood pressure; ABPM, ambulatory blood pressure monitoring; VAS, visual analog scale; ECG, electrocardiogram; 
AE, adverse event; SDLP, standard deviation of lateral position; CRCDS-MiniSim, Cognitive Research Corporation’s driving simulator-MiniSim.
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response with 100 mg was superior to 200 mg and was similar 
to 400 mg. The reason may depend on the small sample sizes 
and the random variation in severity and response of migraine 
attacks. The therapeutic gains for headache responses of 
lasmiditan 100 mg (38%) and 400 mg (39%) are in the same 
range of oral triptans.8 Lasmiditan doses of 200 and 400 mg 
were superior to placebo (19% and 28% vs. 7.4%) for pain 
free at 2 hours (secondary end point), but lasmiditan 100 mg 
(14%) was not. Both doses of lasmiditan, 100 and 400 mg, 
were superior to placebo for improvements in headache sever-
ity, clinical disability, headache recurrence within 24 hours, 
and patients’ global impression of treatment.
Phase III clinical trials
Currently, two Phase III clinical trials and one long-term, 
open-label study are ongoing.63–65
The first trial is a randomized, double-blind, placebo-
controlled parallel group study (COL MIG-301 or SAMU-
RAI, ID number NCT02439320) evaluating the efficacy of 
two doses of lasmiditan (100 and 200 mg) for the outpatient 
treatment of one migraine attack. A second dose within 
24 hours was allowed for rescue or recurrence of migraine.63 
For this study, 2232 patients older than 18 years (with no 
upper age limit) with episodic disabling migraine (assessed 
by the Migraine Disability Assessment score ≥11) were 
enrolled. The primary and secondary end points were the 
proportion of subjects with pain-free headache and the 
proportion of subjects who were free of most bothersome 
migraine-associated symptoms at 2 hours post dose. The most 
bothersome migraine-associated symptom (identified by the 
subjects among nausea, photophobia, and phonophobia) is a 
new end point never used before in migraine therapy. Other 
outcome measures were headache relief (at 2 hours); use of 
rescue medication (at 2 hours and 2–24 hours); headache 
recurrence (within 48 hours); proportion of patients who were 
free of nausea, photophobia, and phonophobia (at 2 hours); 
AEs (up to 11 weeks); and health care resource utilization 
(6 months prior to enter in the study compared with its use 
during the time on study). Both doses showed superiority 
compared to placebo for the primary and several secondary 
end points with statistical significance.
The second trial is a randomized, double-blind, placebo-
controlled parallel group study (COL MIG-302 or SPARTAN, 
ID number NCT02605174) evaluating the efficacy of three 
doses of lasmiditan (50, 100, and 200 mg) for the outpatient 
treatment of one migraine attack.64 The characteristics of the 
enrolled population (3007 subjects), the design, and the end 
points of this study were same as of the SAMURAI trial.
The long-term, open-label trial of lasmiditan (COL MIG-
305 or GLADIATOR, ID number NCT02565186) started in 
October 2015 and is estimated to end in May 2018.65 This is 
a prospective, randomized, open-label study of subjects with 
migraine who have completed SAMURAI or SPARTAN. 
The study is designed to evaluate the safety and tolerability 
(primary end point) of long-term (12 months) intermittent 
use of lasmiditan 100 and 200 mg as the first dose and the 
second dose for the acute treatment of migraine. Long-term 
efficacy (secondary end point) will also be evaluated, as well 
as the 12-month health care resource utilization.
Clinical safety and tolerability
In all studies, lasmiditan did not show the usual side effects 
of triptans. Typical triptan-associated AEs (chest or neck pain, 
tightness, or heaviness) were rare and with a rate similar to 
the placebo-treated groups.56,62 This finding was expected 
considering the different chemical structure of lasmiditan.
Most importantly, cardiac safety of lasmiditan was con-
firmed as no arrhythmia or any proarrhythmic effects were 
observed.61 No pathological abnormalities of any safety param-
eters (i.e., vital parameters, 12-lead electrocardiogram [ECG], 
hematology, biochemistry, and urine analysis) were reported 
following the administration of lasmiditan, for both the intra-
venous and oral formulations (all doses up to 400 mg).56,62
However, this selective 5-HT1
F
 receptor agonist showed a 
high incidence of the central nervous system (CNS)-related 
AEs, probably because of the high CNS permeability through 
the BBB. In one Phase I study, the most common side effect 
was somnolence,58 while in another study, drowsiness, diz-
ziness, and paresthesia were reported as the most frequent 
AEs with the maximum dose of 400 mg.59 In the first Phase 
II trial with the intravenous formulation (20 mg), 65% of 
subjects on lasmiditan and 43% on placebo reported mild 
AEs, and the most common were paresthesia, dizziness, 
and limb heaviness.62 The rate of placebo-subtracted AEs 
for lasmiditan was 25%.
The larger human safety and tolerability data came from 
the oral lasmiditan Phase II study (Table 3).56 AEs of diz-
ziness, paresthesia, vertigo, fatigue, and somnolence were 
reported by 22% of the patients receiving placebo and, in 
a dose-dependent manner, by 65%, 72%, 86%, and 84% of 
patients receiving lasmiditan (50, 100, 200, and 400 mg, 
respectively). The rate of placebo-subtracted AEs was 50% 
for oral lasmiditan 100 mg and was 66% for lasmiditan 
400 mg. Most AEs were mild. However, with lasmiditan 
100 mg, moderate and severe AEs were reported by 46% 
and 27% of patients. At the dose of 400 mg, 60% of subjects 
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reported moderate AEs and 44% of subjects reported severe 
AEs. Thus, almost one-third of patients experienced severe 
CNS-related AEs even with the 100 mg dose. A 46-year-old 
woman had an overnight hospital admission for moderate 
dizziness occurring 30 minutes after taking 200 mg of las-
miditan. ECGs showed sinus bradycardia 1.5 and 4 hours 
after drug intake but no other abnormalities. She received a 
saline infusion and had complete recovery by the next day. 
The AE was classified as serious.
In the first Phase III trial (SAMURAI study), lasmiditan 
was tolerated and, as in the Phase II studies, most AEs were 
related to the CNS or the vestibular system.66 The most com-
mon side effect was dizziness (11.9% and 15.4% for lasmidi-
tan 100 and 200 mg, respectively, vs. 3.1% for placebo). Other 
common AEs were paresthesia, nausea, somnolence, and 
fatigue. AEs were reported to be mild or moderate in 91% of 
the cases, and some of them (dizziness and vertigo) occurred 
less frequently than those observed in the Phase II trials.
Migraine pathophysiology: how does 
an acute treatment work?
The pathophysiology of migraine still remains not completely 
clear, but the current view considers this primary headache 
as a disorder in which the brain, meningeal blood vessels, 
and the trigeminal nerve system play a crucial role.67 The 
current standard pharmacotherapies have been developed 
when migraine was believed to be primarily a vascular dis-
ease depending on the abnormal vasodilation of intracranial 
vessels.68 Hence, it was supposed that constriction of dilated 
cerebral blood vessels could block a migraine attack.
Although the vascular hypothesis was reinforced by the 
efficacy of 5-HT1
B
 receptor agonists (triptans), which act as 
potent cerebral vasoconstrictors, it has been overtaken by 
the neurogenic hypothesis. Recent experimental evidences 
suggest that migraine is primarily a neuronal disease.67,69,70 
According to this model, cranial vasodilation is not the 
primum movens but only an epiphenomenon in migraine 
pathophysiology. The primary cause is supposed to be the 
activation and sensitization of the trigeminal nerve system 
innervating the large vessels in the meninges.71 These pro-
cesses lead to neuropeptide release, particularly CGRP, which 
is a well-known vasodilatator, and a subsequent increase in 
vessel diameter and blood flow in the meninges and cortex. In 
the cascade of events, the following excitation of secondary 
and tertiary central trigeminal neurons may activate cortical 
and subcortical areas, giving a reason to the pain and other 
typical migraine symptoms.72
Triptans may act also through neural mechanisms, more 
likely inhibiting neuropeptide release (i.e., CGRP) from 
trigeminal neurons and consequently blocking transmission 
of pain signals within the trigeminal cervical complex.73 The 
neurogenic hypothesis implies the possibility that vasocon-
striction is not essential for antimigraine therapy and that 
migraine may be aborted inhibiting central or peripheral 
nervous system mechanisms. In this view, CGRP receptor 
antagonists (gepants) seemed to be promising alternatives to 
triptans, but, even if effective, their development was inter-
rupted because of the concern regarding hepatotoxicity.74
Recently, 5-HT1
F
 receptors, expressed by trigeminal 
neurons, trigeminal ganglion, and trigeminal nucleus cau-
dalis and lacking vasoconstrictive effects, were thought as 
an ideal target for migraine abortive drug development.75,76 
Specifically, lasmiditan has a peculiar and unique chemical 
structure that avoids typical triptans-related side effects (e.g., 
neck, jaw, and chest symptoms) and makes it able to cross 
the BBB and act both centrally on trigeminal neurons and 
Table 3 Treatment-emergent and severe AEs after placebo and oral lasmiditan (50–400 mg)
AEs Placebo  
(n=19/86; 22%)
Lasmiditan 50 mg  
(n=53/82; 65%)
Lasmiditan 100 mg  
(n=59/82; 72%)
Lasmiditan 200 mg  
(n=61/71; 86%)
Lasmiditan 400 mg  
(n=59/70; 84%)
Treatment 
emergent
Severe Treatment 
emergent
Severe Treatment 
emergent
Severe Treatment 
emergent
Severe Treatment 
emergent
Severe
Dizziness 0 (0%) 0 (0%) 19 (23%) 1 (1%) 21 (26%) 8 (10%) 27 (38%) 11 (15%) 26 (37%) 12 (17%)
Fatigue 2 (2%) 1 (1%) 10 (12%) 5 (6%) 17 (21%) 7 (9%) 15 (21%) 11 (15%) 16 (23%) 7 (10%)
Vertigo 1 (1%) 0 (0%) 8 (10%) 1 (1%) 12 (15%) 3 (4%) 12 (17%) 3 (4%) 16 (23%) 7 (10%)
Somnolence 2 (2%) 1 (1%) 8 (10%) 3 (4%) 10 (12%) 2 (2%) 8 (11%) 2 (3%) 8 (11%) 2 (3%)
Paresthesia 2 (2%) 0 (0%) 2 (2%) 1 (1%) 9 (11%) 2 (2%) 12 (17%) 4 (6%) 14 (20%) 5 (7%)
Nausea 0 (0%) 0 (0%) 4 (5%) 2 (2%) 8 (10%) 0 (0%) 2 (3%) 1 (1%) 5 (7%) 0 (0%)
Sensation of 
heaviness
1 (1%) 1 (1%) 4 (5%) 3 (4%) 4 (5%) 1 (1%) 7 (10%) 2 (3%) 5 (7%) 3 (4%)
Note: The first row reports the occurrence rate (%) of treatment-emergent events calculated as the ratio between subjects experiencing an AE (n) and the total population in 
each treatment group. Modified from Lancet Neurol, 11(5) Farkkila M, Diener HC, Geraud G, et al, Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for 
the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study, 405–413, Copyright (2012), with permission from Elsevier.56
Abbreviation: AE, adverse event.
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peripherally on primary trigeminal afferents and cell bodies 
within the trigeminal ganglion.77
In Phase II and III trials, lasmiditan proved to be an effec-
tive acute treatment for migraine attacks with an AE profile 
exclusively related to CNS, depending on its penetration 
through the BBB. By stimulation of the 5-HT1
F
 receptors, 
lasmiditan may inhibit central and peripheral neuronal activi-
ties and the neuropeptide release (e.g., CGRP), thereby ter-
minating acute migraine.75,78,79 Because of this mechanism of 
action and the absence of vasoconstrictor activity, lasmiditan 
is considered the first of the new drug class, the NAAMAs.
Lasmiditan has a high selectivity for the 5-HT1
F
 recep-
tors, which cannot be found on endothelial or smooth muscle 
cells of cerebral vessels.80 Moreover, its binding profile avoids 
potential AEs of the activation of 5-HT1
B
 receptors in periph-
eral blood vessels, particularly the coronary arteries.10,69 
Based on its lack of vasoconstriction, this substance could 
serve as a treatment option for subjects with cardiovascular 
diseases to whom triptans are contraindicated.
Expert opinion
Conclusion
Almost 30 years have passed since the introduction of trip-
tans. They represented a major breakthrough in the acute 
treatment of migraine but are contraindicated in patients 
with previous cardio- and cerebrovascular diseases and in 
those with uncontrolled hypertension. Unfortunately, a high 
percentage of patients are not satisfied with this acute treat-
ment, either for lack of response or for side effects. Since 
their introduction, no other acute drug class has passed all 
developmental stages.
Lasmiditan is a new effective drug with no vasoconstric-
tive action and a CNS-related AE profile.
There are some open questions that hopefully will find 
answers in future studies.
First of all, the serious matter of medication overuse 
headache (MOH).81 The pathophysiology of MOH is largely 
unknown, but both human and animal studies suggest modi-
fications of the pain network. An excessive use of any of the 
acute drug classes (either specific or not) can cause headache to 
worsen and increase in frequency, and become less responsive 
to both acute and preventative medications.82 This leads to a 
vicious circle that is sometimes difficult to break. For triptans 
(5-HT1
B
/1
D
 agonists), the cutoff for the overuse is ≥15 days/
month (for at least 3 months). Lasmiditan, as triptans, is a 5-HT 
agonist, but it differs for a unique chemical structure and for 
a high selectivity for the 5-HT1
F
 subtype. However, there is 
the possibility that overuse of lasmiditan will lead to MOH.
A second important matter is the use of lasmiditan during 
pregnancy and breastfeeding. This concern is of paramount 
importance, thinking that migraine is more frequent in 
women and particularly during the fertile period of their life. 
Triptans do not seem to increase the rates of major congenital 
malformations, but children exposed to triptans in utero might 
have a higher risk of developing externalizing behaviors.17 
They are considered probably compatible with breastfeeding. 
Lasmiditan, as triptans, is a high lipophilic molecule that 
in Phase II and III studies showed a safety profile different 
from the 5-HT1
B
/1
D
 agonists, with most of the AEs being 
related to CNS. This could limit their use during pregnancy 
and breastfeeding.
Future Phase III clinical trials will determine whether las-
miditan will become available in the market, and then active 
triptan comparator studies will assess patients’ preference.
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